An investigation on behalf of investors of Liquidia Corporation (NASDAQ: LQDA) shares over potential securities laws violations by Liquidia Corporation and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Liquidia Corporation (NASDAQ: LQDA) concerning whether a series of statements by Liquidia Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Morrisville, NC based Liquidia Corporation, through its subsidiaries, operates as a late-stage clinical biopharmaceutical company.

On November 25, 2020, Liquidia Corporation announced that the U.S. Food and Drug Administration ('FDA') had issued a complete response letter ('CRL') for the Company's New Drug Application ('NDA') for LIQ861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension. Specifically, Liquidia Corporation advised, among other things, that '[i]n the CRL, the FDA stated that it is unable to approve the NDA at this time,' citing 'the need for additional information and clarification on chemistry, manufacturing and controls (CMC) data pertaining to the drug product and device biocompatibility.'

Shares of Liquidia Corporation (NASDAQ: LQDA) declined from $4.94 per share on November 11, 2020, to as low as $2.70 per share on November 25, 2020.